Compare Torrent Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GLENMARK PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GLENMARK PHARMA TORRENT PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 36.7 17.7 207.0% View Chart
P/BV x 9.3 2.9 319.0% View Chart
Dividend Yield % 0.7 0.3 189.6%  

Financials

 TORRENT PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
TORRENT PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,964712 276.0%   
Low Rs1,245484 257.4%   
Sales per share (Unadj.) Rs453.4349.6 129.7%  
Earnings per share (Unadj.) Rs25.832.8 78.7%  
Cash flow per share (Unadj.) Rs62.344.3 140.5%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.10.3 316.6%  
Book value per share (Unadj.) Rs279.2198.6 140.5%  
Shares outstanding (eoy) m169.22282.17 60.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.51.7 207.0%   
Avg P/E ratio x62.218.2 341.4%  
P/CF ratio (eoy) x25.813.5 191.1%  
Price / Book Value ratio x5.73.0 191.0%  
Dividend payout %65.96.1 1,080.7%   
Avg Mkt Cap Rs m271,513168,625 161.0%   
No. of employees `00013.612.0 113.0%   
Total wages/salary Rs m14,03820,561 68.3%   
Avg. sales/employee Rs Th5,642.68,196.0 68.8%   
Avg. wages/employee Rs Th1,032.41,708.1 60.4%   
Avg. net profit/employee Rs Th320.9768.5 41.8%   
INCOME DATA
Net Sales Rs m76,72898,655 77.8%  
Other income Rs m5712,081 27.4%   
Total revenues Rs m77,299100,736 76.7%   
Gross profit Rs m19,83115,858 125.1%  
Depreciation Rs m6,1773,259 189.5%   
Interest Rs m5,0383,346 150.6%   
Profit before tax Rs m9,18711,335 81.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5701,672 -213.5%   
Tax Rs m1,2543,756 33.4%   
Profit after tax Rs m4,3639,250 47.2%  
Gross profit margin %25.816.1 160.8%  
Effective tax rate %13.633.1 41.2%   
Net profit margin %5.79.4 60.6%  
BALANCE SHEET DATA
Current assets Rs m50,37566,968 75.2%   
Current liabilities Rs m51,65340,211 128.5%   
Net working cap to sales %-1.727.1 -6.1%  
Current ratio x1.01.7 58.6%  
Inventory Days Days9283 110.5%  
Debtors Days Days6881 84.1%  
Net fixed assets Rs m83,64833,322 251.0%   
Share capital Rs m846282 299.9%   
"Free" reserves Rs m46,39755,770 83.2%   
Net worth Rs m47,24456,052 84.3%   
Long term debt Rs m39,12935,738 109.5%   
Total assets Rs m141,209132,888 106.3%  
Interest coverage x2.84.4 64.4%   
Debt to equity ratio x0.80.6 129.9%  
Sales to assets ratio x0.50.7 73.2%   
Return on assets %6.79.5 70.2%  
Return on equity %9.216.5 56.0%  
Return on capital %12.317.8 69.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10362,998 35.1%   
Fx outflow Rs m5,52222,859 24.2%   
Net fx Rs m16,58140,140 41.3%   
CASH FLOW
From Operations Rs m17,98113,242 135.8%  
From Investments Rs m-2,413-6,990 34.5%  
From Financial Activity Rs m-13,145-7,387 177.9%  
Net Cashflow Rs m2,380-2,971 -80.1%  

Share Holding

Indian Promoters % 71.5 48.3 148.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 6.9 101.7%  
FIIs % 12.6 34.4 36.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 56,727 46.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT PHARMOVA   DIVIS LABORATORIES  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 19, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS